Among them, the TLR9 agonist showed improved therapeutic effects, whether used alone or in combination with other drugs, immunocheckpoint blocking therapy, or as an adjuvant of a tumour vaccine [62, 63]. This evidence concerns the gene TLR9 and neoplasm.